ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO1001

Psoralen Ameliorates Renal Fibrosis Induced by Unilateral Ureteral Obstruction in Mice

Session Information

  • CKD: Pathobiology - I
    November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2203 CKD (Non-Dialysis): Mechanisms

Authors

  • Lee, Tae won, Gyeongsang National University Changwon Hospital, Changwon, Gyeongsangnam-do, Korea (the Republic of)
  • Bae, Eunjin, Gyeongsang National University Changwon Hospital, Changwon, Gyeongsangnam-do, Korea (the Republic of)
  • Chang, Se-Ho, Gyeongsang National University Hospital, Jinju, Gyeongsangnam-do, Korea (the Republic of)
  • Park, Dong Jun, Gyeongsang National University Changwon Hospital, Changwon, Gyeongsangnam-do, Korea (the Republic of)
Background

Renal fibrosis arises in most progressive renal diseases, regardless of the disease underlying end-stage kidney disease. Psoralen (PSO), a major active component extracted from Psoralea corylifolia L. seed, has several biological effects. However, the role of psoralen in renal fibrosis is still unclear. This study was undergone to evaluate the PSO on the development and progression of renal fibrosis induced by unilateral ureteral obstruction (UUO) in mice model.

Methods

The mice were divided into four groups: PSO (20 mg/kg, i.g., n = 5), PSO + Sham (n = 5), UUO (n = 10), and PSO + UUO (n = 10). PSO was intragastrically administered 24 hour before the UUO and continued afterward for 7 days and all mice were killed 7 days after UUO.

Results

Severe tubular atrophy, tubular injury, and tubulointerstitial fibrosis were significantly developed in UUO mice. Higher expression of TGF-β1 is accompanied by elevated alpha-SMA and p-Smad2/3 after 7 post-UUO. However, PSO treatment reduced tubular injury and interstitial fibrosis and the expression of TGF-β1, alpha-SMA, and p-Smad2/3. Futhermore, level of macrophages (represented by F4/80 positive cells) and inflammasome reflected by inflammasome markers such as NLRP3 and cCASP-1 were significantly decreased by PSO treatment.

Conclusion

This is the first study to show that PSO reduces renal fibrosis in UUO mice model. These results suggest that PSO had merits of further exploration as a therapeutic agent in the management of chronic kidney disease.